The recent activity surrounding United Therapeutics Corp (NASDAQ:UTHR) features notable insider transactions juxtaposed against significant operational updates, including positive clinical data and mixed quarterly financial results. On May 26, 2026, Martine A. Rothblatt, Chairperson and CEO of the company, executed a sale of 1,500 shares of UTHR's common stock.
These transactions collectively accounted for a total value of $863,947. The shares were sold across a price range spanning from $575.51 to $576.50, resulting in a weighted average sale price of $575.9649 per share. It is important to note that this disposition was managed through a pre-arranged 10b5-1 trading plan. Ms. Rothblatt initially adopted this plan on November 7, 2025.
The underlying 10b5-1 plan mechanism involves the exercise of 1,734,410 stock options that are scheduled to expire on March 17, 2027. This specific trading plan is designed to remain active until December 31, 2026, or until all associated options have been exercised, whichever occurs first. Following the recent sale of shares, Ms. Rothblatt's direct holdings in United Therapeutics common stock amount to 43,153 shares.
In other financial context, UTHR maintains a robust overall financial standing, boasting a market capitalization of $22.95 billion and demonstrating an impressive gross profit margin of 87%. For investors seeking deeper analysis into the company's valuation metrics and general financial health, comprehensive resources are available through InvestingPro, which provides detailed Pro Research Reports covering over 1,400 US equities.
Clinical Progress and Corporate Developments
In separate corporate news, United Therapeutics Corporation announced a major clinical achievement regarding its drug candidate, Tyvaso. Specifically, the TETON-1 phase 3 study evaluating nebulized Tyvaso for idiopathic pulmonary fibrosis successfully met its primary endpoint. The published results in the New England Journal of Medicine indicated that Tyvaso was effective in preserving lung function and reducing the risk associated with clinical worsening events.
Furthermore, UTHR reported its first-quarter financial results. Total revenue reached $781.5 million for the quarter, which failed to meet the consensus estimate of $797.4 million. The performance of Tyvaso was also highlighted, with its associated revenue totaling $457.5 million, falling short of the expected $478.6 million. On the bottom line, net income for the period stood at $274.9 million, which was below the anticipated figure of $320.5 million.
Following these earnings reports, BTIG reiterated a Neutral rating on the stock. Conversely, TD Cowen maintained a Buy rating and set a price target of $675.00 for United Therapeutics. The company also announced a strategic partnership with Varda Space Industries. This collaboration is aimed at exploring pharmaceutical processing in microgravity conditions to benefit rare pulmonary diseases, intending to enhance both the stability and delivery mechanisms of therapeutic compounds.
Market Context and Valuation
The stock's performance context shows that while it delivered a strong 67% return over the past year, its current trading price is reported at $540. This figure remains slightly above InvestingPro’s established Fair Value estimate.
The overall market activity for UTHR showed recent fluctuations, with observed data points including a closing price of $539.97 and an after-hours price of $534.50, reflecting daily volatility.